News
SLNO
--
0.00%
--
Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fir...
GlobeNewswire · 10h ago
Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate ...
GlobeNewswire · 09/16 20:05
Soleno Therapeutics' DCCR Shows Benefit On Hunger, Behavioral Parameters
Benzinga · 09/08 15:15
BRIEF-Soleno Says DCCR Shows Continued Improvements In PWS Symptoms Following One Year Treatment
reuters.com · 09/08 12:15
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
Figure 1 Change from Pre-DCCR HQ-CT Total Score After 13, 26, 39, and 52 Weeks Figure 2 Change in HQ-CT after 26 Weeks and 52 Weeks for DCCR Compared to PfPWS Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Stu...
GlobeNewswire · 09/08 12:00
Soleno Says Study Shows 'Significant' Improvement in Symptoms in Prader-Willi Syndrome Patients
MT Newswires · 09/08 11:19
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Insider Selling at Soleno Therapeutics (SLNO) is Significant
MT Newswires · 08/04 22:33
Insider Trends: Soleno Therapeutics Insider Continues 90-Day Selling Trend
MT Newswires · 08/03 18:55
BRIEF-Soleno Therapeutics Q2 Loss Per Share $0.14
reuters.com · 07/28 22:14
BRIEF-Soleno Therapeutics Provides Corporate Update And Reports Second Quarter 2021 Financial Results
reuters.com · 07/28 20:41
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26)
Benzinga · 07/27 11:48
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19)
Benzinga · 07/20 12:19
Stocks That Hit 52-Week Lows On Monday
  Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
Benzinga · 07/19 14:04
BRIEF-Soleno Therapeutics - On July 16 Entered Into Controlled Equity Offering Sales Agreement With Cantor Fitzgerald
reuters.com · 07/16 20:18
FDA maintains additional trial necessary for Soleno's Prader-Willi Syndrome candidate
Sarah Silbiger/Getty Images News The FDA has again informed Soleno Therapeutics ([[SLNO]] -1.8%) that an additional clinical trial is necessary for in order to submit an NDA for once-daily DCCR
Seekingalpha · 07/06 16:10
BRIEF-Soleno Therapeutics Provides Regulatory Update On Dccr For The Treatment Of Prader-Willi Syndrome
reuters.com · 07/06 12:38
Soleno Therapeutics Says On Jul. 2 Received Official meeting Minutes From Type B FDA Meeting; FDA Continued To Assert That Based On Data, Additional Trial Is Necessary For NDA But Encouraged Co. To Submit Available Data
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following a recent
Benzinga · 07/06 12:06
Webull provides a variety of real-time SLNO stock news. You can receive the latest news about SOLENO THERAPEUT through multiple platforms. This information may help you make smarter investment decisions.
About SLNO
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for the treatment of rare diseases. Its lead drug Diazoxide Choline Controlled-Release tablets (DCCR) is a potent ATP-sensitive potassium (KATP) channel activator. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like Prader-Willi syndrome (PWS) to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. It appears that many of the problematic behaviors in conditions like PWS may have hyperphagic drive as a root cause and may therefore be improved by addressing hyperphagia. The Company has a Fast-Track designation for DCCR in PWS and orphan drug designation for the drug in the United States and European Union.